Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arrowhead Pharma (ARWR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,061,521
  • Shares Outstanding, K 88,020
  • Annual Sales, $ 31,410 K
  • Annual Income, $ -34,380 K
  • 36-Month Beta 2.07
  • Price/Sales 71.21
  • Price/Cash Flow N/A
  • Price/Book 10.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.15
  • Number of Estimates 4
  • High Estimate -0.07
  • Low Estimate -0.22
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -7.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.83 +9.38%
on 11/15/18
16.09 -19.58%
on 11/08/18
-0.21 (-1.60%)
since 10/15/18
3-Month
11.83 +9.38%
on 11/15/18
22.39 -42.21%
on 09/06/18
-1.81 (-12.27%)
since 08/15/18
52-Week
3.01 +329.90%
on 12/13/17
22.39 -42.21%
on 09/06/18
+9.35 (+260.45%)
since 11/15/17

Most Recent Stories

More News
Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting(R) 2018

--Reductions were sustained for greater than 14 weeks indicating that quarterly or less frequent dosing appears feasible

ARWR : 12.97 (+7.55%)
Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting(R) 2018

--- ARO-HBV appears to be well-tolerated at monthly doses up to 400 mg

ARWR : 12.97 (+7.55%)
Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events:

ARWR : 12.97 (+7.55%)
Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the license agreement and research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc.,...

ARWR : 12.97 (+7.55%)
JNJ : 144.51 (+0.18%)
Market Trends Toward New Normal in IAC/InterActiveCorp, Eagle Pharmaceuticals, Arrowhead Pharmaceuticals, The Manitowoc, Brookdale Senior Living, and LATAM Airlines Group S.A -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of IAC/InterActiveCorp (NASDAQ:IAC),...

MTW : 19.04 (+2.59%)
ARWR : 12.97 (+7.55%)
LTM : 9.59 (+4.35%)
EGRX : 50.41 (+1.88%)
IAC : 185.33 (+2.56%)
BKD : 8.52 (+0.24%)
Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting(R) 2018

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) will make two late-breaking poster presentations at The Liver Meeting(R) 2018, the Annual Meeting of the American Association for the Study of...

ARWR : 12.97 (+7.55%)
Major Biotech Announcements Moving the Market

HENDERSON, NV / ACCESSWIRE / October 10, 2018 / The biotech market is moved by events and announcements. There are a few major events currently impacting the companies highlighted below.

ARWR : 12.97 (+7.55%)
PPCHD : 1.2000 (+20.00%)
DVAX : 12.03 (+4.79%)
NVAX : 1.78 (+6.59%)
Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates

Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.

ABUS : 4.57 (+4.34%)
ARWR : 12.97 (+7.55%)
JNJ : 144.51 (+0.18%)
GILD : 69.79 (-1.08%)
J&J Inks Deal With Arrowhead for Promising Liver Candidate

Johnson & Johnson (JNJ) signs a licensing pact with Arrowhead to develop the latter's RNAi therapy candidate, ARO-HBV, for treating chronic hepatitis B viral infection. The deal is worth $3.7 billion.

ARWR : 12.97 (+7.55%)
JNJ : 144.51 (+0.18%)
ALNY : 69.45 (+6.73%)
RHHBY : 30.9340 (+0.21%)
Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Amarin

NEW YORK, NY / ACCESSWIRE / October 5, 2018 / U.S. markets plunged on Thursday as the 10-year U.S. treasury note hit its highest level since 2011, dampening investors' enthusiasm for stocks. The Dow Jones...

ARWR : 12.97 (+7.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ARWR with:

Business Summary

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes....

See More

Key Turning Points

2nd Resistance Point 13.23
1st Resistance Point 12.65
Last Price 12.97
1st Support Level 11.66
2nd Support Level 11.25

See More

52-Week High 22.39
Fibonacci 61.8% 14.99
Last Price 12.97
Fibonacci 50% 12.70
Fibonacci 38.2% 10.41
52-Week Low 3.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar